Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources

ESMO Congress 2023

20 - 24 Oct 2023

Madrid, Spain

ESMO-Congress-2023-1000x1000

Resources are available according to the presenters' agreement to release them.

  • Abstracts and ePosters are open access.
  • Slides and webcasts are reserved to ESMO Members and registered Delegates.

The copyright protected educational resources from this event are for personal usage only and not to be shared with any third parties. ESMO thanks the authors for their generosity.

Meeting programme Next/upcoming meetings
For healthcare professionals, researchers, and those interested in the ever-evolving field of cancer research and care

A comprehensive update covering recent breakthroughs in basic science, translational research, and clinical study results, as well as prevention, screening, and early diagnosis. The programme aimed at helping participants to understand the clinical implications of these advancements, especially in cancer biology, diagnostics, treatments, and educate on the optimal use of new diagnostic tools and therapies for patients with cancer. Abstract Book of the ESMO Congress 2023

Video coverage: Highlights    Expert reports    Breaking Science in Breast Cancer 
ESMO Members, read our Congress Watch articles

Quick access to special sessions

Clinical Practice Guidelines sessions (open to ESMO account holders):
- Session 1  covering early Breast Cancer, Oncogene-addicted mNSCLC, Pancreatic Cancer
- Session 2 covering non-oncogene-addicted mNSCLC, SCCHN, Prostate Cancer

ESMO Colloquia slides & webcasts

Satellite webcasts from our Industry partners

Hide
Filter by:
Search:
Reset

There are 3397 resources available

No

Presenter: Rebecca Lee

Session: All patients with resected stage IIB/IIC should be treated with adjuvant anti-PD1 therapy

Resources:

Slides

Webcast

First voting

Presenter: Georgina Long

Session: All patients with resected stage IIB/IIC should be treated with adjuvant anti-PD1 therapy

Resources:

Slides

Webcast

Perspective from the Chair

Presenter: Georgina Long

Session: All patients with resected stage IIB/IIC should be treated with adjuvant anti-PD1 therapy

Resources:

Slides

Webcast

Discussion

Presenter: All Speakers

Session: Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases

Resources:

Slides

Webcast

Second voting

Presenter: Georgina Long

Session: All patients with resected stage IIB/IIC should be treated with adjuvant anti-PD1 therapy

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.